SVRA
NASDAQ · Biotechnology
Savara Inc
$5.50
+0.12 (+2.23%)
Open$5.51
Previous Close$5.38
Day High$5.63
Day Low$5.37
52W High$7.01
52W Low$1.98
Volume—
Avg Volume1.84M
Market Cap1.13B
P/E Ratio—
EPS$-0.56
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+1,044.4% upside
Current
$5.50
$5.50
Target
$62.94
$62.94
$52.50
$62.94 avg
$80.97
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 135.25M | 127.87M | 115.53M |
| Net Income | 19.67M | 13.91M | 14.59M |
| Profit Margin | 14.5% | 10.9% | 12.6% |
| EBITDA | 27.67M | 31.26M | 23.85M |
| Free Cash Flow | 12.49M | 17.00M | 15.12M |
| Rev Growth | +10.1% | -5.7% | +15.6% |
| Debt/Equity | 0.38 | 0.46 | 0.53 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |